Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis

Company Overview

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders. KIO-100 has completed initial Phase 1 safety studies, demonstrating tolerability and preliminary signs of localized immune modulation without systemic exposure.

Kiora’s second program, KIO-301, leverages optogenetic therapy to introduce light-sensitive proteins into retinal cells, offering a potential treatment for retinitis pigmentosa and other degenerative retinal diseases. This platform aims to restore visual function by converting surviving retinal neurons into artificial photoreceptors, and it is currently advancing through preclinical development and manufacturing scale-up.

Headquartered in the United States, Kiora collaborates with academic institutions and contract research organizations to support its clinical and preclinical programs. The company’s leadership team comprises experienced executives and scientists drawn from both ophthalmology and biotechnology sectors, all working toward delivering novel treatments for patients with unmet visual needs.

Key Stats

• Today's Range: $2.59 to $2.65
• 50-Day Range: $2.46 to $2.75
• 52-Week Range: $1.76 to $2.95
• Volume: 10,485 shs
• Average Volume: 12,595 shs
• Market Capitalization: $11.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Kiora Pharmaceuticals Stock Analysis - MarketRank™

Kiora Pharmaceuticals scored higher than 14% of companies evaluated by MarketBeat, and ranked 854th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Kiora Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Kiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kiora Pharmaceuticals is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kiora Pharmaceuticals is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kiora Pharmaceuticals has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Kiora Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Kiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kiora Pharmaceuticals has recently increased by 19.54%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kiora Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Kiora Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.63

News Sentiment

Kiora Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Kiora Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.52% of the stock of Kiora Pharmaceuticals is held by insiders.

Percentage Held by Institutions

76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:KPRX
• CIK: 1372514
• Web: eyegatepharma.com
• Phone: (781) 788-9043
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.38%
• Return on Assets: -44.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.97
• Quick Ratio: 8.97

Sales & Book Value

• Annual Sales: $16.02 million
• Price / Sales: 0.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.38 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 4,420,000
• Free Float: 4,401,000
• Market Cap: $11.71 million
• Optionable: Not Optionable
• Beta: -0.34